Roche will discontinue its agreement with PDL BioPharma, Inc. for the development and commercialization of daclizumab for organ transplant patients on longer-term maintenance therapy. This decision follows an internal review of its development programs. Earlier this year, Roche discontinued its involvement in the co-development of daclizumab for the treatment of asthma. The agreement between the two companies will end in May 2007. PDL will hold exclusive development and commercial rights to...